Opinion

Video

Disease Progression Beyond Frontline KRAS G12C Inhibitors

Expert oncologists discuss patients who may progress to the second line setting with KRAS G12C mutations.

Related Videos
3 experts are featured in this series.
3 experts are featured in this series.
Dr Cascone on Evaluating Neoadjuvant Durvalumab-Based Regimens in Resectable NSCLC
2 expert is featured in this series.
2 expert is featured in this series.